Dermatitis  >>  triamcinolone acetonide  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
triamcinolone acetonide / Generic mfg.
CHRONOS, NCT02260986 / 2013-003254-24: Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Checkmark CHRONOS trial in moderate-to-severe AD at AAD 2017
Mar 2017 - Mar 2017: CHRONOS trial in moderate-to-severe AD at AAD 2017
Checkmark LIBERTY AD CHRONOS study for atopic dermatitis
Jul 2016 - Jul 2016: LIBERTY AD CHRONOS study for atopic dermatitis
Checkmark Interim results from CHRONOS trial for atopic dermatitis
More
Completed
3
740
Japan, US, Canada, Europe, RoW
Dupilumab, REGN668, SAR231893, Dupixent, Placebo (for Dupilumab), Topical Corticosteroid (TCS)
Regeneron Pharmaceuticals, Sanofi
Atopic Dermatitis
08/15
10/16
LIBERTY AD PEDS, NCT03345914 / 2016-004997-16: Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

Checkmark Efficacy data in children aged 6 to 11 years with uncontrolled severe atopic dermatitis at the 2020 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference
Apr 2020 - Apr 2020: Efficacy data in children aged 6 to 11 years with uncontrolled severe atopic dermatitis at the 2020 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference
Checkmark Positive results in 6 to 11 years children with severe atopic dermatitis
Aug 2019 - Sep 2019: Positive results in 6 to 11 years children with severe atopic dermatitis
Completed
3
367
Europe, Canada, US, RoW
Dupilumab, DUPIXENT®, REGN668, SAR231893, Matching Placebo, Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers
Regeneron Pharmaceuticals, Sanofi
Dermatitis, Atopic
06/19
09/19
AD Up, NCT03568318 / 2017-005126-37: A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Enrolling by invitation
3
1500
Europe, Canada, Japan, US, RoW
Placebo, Upadacitinib, ABT-494, RINVOQ™, Topical corticosteroids (TCS)
AbbVie
Atopic Dermatitis
02/21
11/30
NCT05535738: Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Recruiting
2/3
45
US
Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab, Adalimumab, Ustekinumab, Guselkumab, Canakinumab, Sarilumab, Triamcinolone Acetonide, Betamethasone Valerate, Fluticasone Propionate, Microneedle, Suction blistering, Skin punch biopsy
John Harris
Skin Inflammation, Allergic Contact Dermatitis
01/27
12/27

Download Options